{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T04:45:19Z","timestamp":1648874719490},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T00:00:00Z","timestamp":1441756800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s00393-014-1487-8","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T13:35:21Z","timestamp":1441632921000},"page":"682-688","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biosimilars in der Rheumatologie"],"prefix":"10.1007","volume":"74","author":[{"given":"R.","family":"Alten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,9]]},"reference":[{"key":"1487_CR1","unstructured":"Patient Protection and Affordable Care Act. Congress of the United States (2010)"},{"key":"1487_CR2","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W et al (2010) Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med 362:1383\u20131395","journal-title":"N Engl J Med"},{"key":"1487_CR3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10637-012-9899-2","volume":"31","author":"Dranitsaris","year":"2013","unstructured":"Dranitsaris G, Dorward K, Hatzimichael E et al (2013) Clinical trial design in biosimilar drug development. Invest New Drugs 31:479\u2013487","journal-title":"Invest New Drugs"},{"key":"1487_CR4","unstructured":"Assessment report. Inflectra. European Medicines Agency. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002778\/WC500151490.pdf. Published 2013"},{"key":"1487_CR5","unstructured":"European public assessment reports-Biosimilars. European Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter keywords&searchType=name&alreadyLoaded=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&jsenabled=false&searchGenericType=biosimilars&orderBy=authDate&pageNo=1. Published 2014"},{"key":"1487_CR6","unstructured":"Guideline on Similar Biological Medical Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. European Medicines Agency. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/06\/WC500144124.pdf. Published 2013"},{"key":"1487_CR7","unstructured":"FDA accepts biosimilar filgrastim application. GaBI Online. http:\/\/www.gabionline.net\/Biosimilars\/News\/FDA-accepts-biosimilar-filgrastim-application. Published 2014"},{"key":"1487_CR8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-203198","volume":"72","author":"Kay","year":"2013","unstructured":"Kay J, Smolen JS (2013) Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 72:1589\u20131593","journal-title":"Ann Rheum Dis"},{"key":"1487_CR9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","volume":"46","author":"Klotz","year":"2007","unstructured":"Klotz U, Teml A, Schwab M (2007) Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 46:645\u2013660","journal-title":"Clin Pharmacokinet"},{"key":"1487_CR10","doi-asserted-by":"crossref","unstructured":"Landewe RBM, Van Der Heijde DMFM (2013) Clinical trial design and analysis. In: Firestein GS, Budd RC, Gabriel SE et al (Hrsg) Kelley\u2019s textbook of rheumatology, 9. Aufl. Elsevier, Philadelphia, PA, 32-1-32-10","DOI":"10.1016\/B978-1-4377-1738-9.00032-3"},{"key":"1487_CR11","first-page":"102","volume":"30","author":"Lapadula","year":"2012","unstructured":"Lapadula G, Ferraccioli GF (2012) Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol 30:102\u2013106","journal-title":"Clin Exp Rheumatol"},{"key":"1487_CR12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S et al (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72:1605\u20131612","journal-title":"Ann Rheum Dis"},{"key":"1487_CR13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/apt.12477","volume":"38","author":"Rinaudo-Gaujous","year":"2013","unstructured":"Rinaudo-Gaujous M, Paul S, Tedesco ED et al (2013) Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 38:914\u2013924","journal-title":"Aliment Pharmacol Ther"},{"key":"1487_CR14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85\u201395 (quiz e14\u201385)","journal-title":"Gastroenterology"},{"key":"1487_CR15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","volume":"146","author":"Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:96\u2013109","journal-title":"Gastroenterology"},{"key":"1487_CR16","first-page":"430","volume":"8","author":"Scheinberg","year":"2012","unstructured":"Scheinberg MA, Kay J (2012) The advent of biosimilar therapies in rheumatology \u2013 \u201eO brave new world\u201c. Nature reviews. Rheumatology 8:430\u2013436","journal-title":"Rheumatology"},{"key":"1487_CR17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"Schett","year":"2013","unstructured":"Schett G, Elewaut D, Mcinnes IB et al (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 19:822\u2013824","journal-title":"Nat Med"},{"key":"1487_CR18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/imj.12292","volume":"44","author":"Strand","year":"2014","unstructured":"Strand V, Cronstein B (2014) Biosimilars: how similar? Intern Med J 44:218\u2013223","journal-title":"Intern Med J"},{"key":"1487_CR19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2011.08.034","volume":"66","author":"Strober","year":"2012","unstructured":"Strober BE, Armour K, Romiti R et al (2012) Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 66:317\u2013322","journal-title":"J Am Acad Dermatol"},{"key":"1487_CR20","unstructured":"Guidance for Industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. US Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm397017.pdf. Published 2014"},{"key":"1487_CR21","unstructured":"Guidance for Industry. Formal meetings between the FDA and biosimilar biological product sponsors or applicants. US Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM345649.pdf. Published 2013"},{"key":"1487_CR22","unstructured":"Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). World Health Organization. http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Published 2009"},{"key":"1487_CR23","unstructured":"Guidance for Industry. Adaptive design clinical trials for drugs and biologics. US Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/ucm201790.pdf. Published 2010"},{"key":"1487_CR24","unstructured":"Guidance for Industry. Non-inferiority clinical trials. US Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM202140.pdf. Published 2010"},{"key":"1487_CR25","unstructured":"Velengtas P, Mohr P, Messner DA (2012) National Pharmaceutical Council. Making informed decisions: assessing the strengths and weaknesses of study designs and analytic methods for comparative effectiveness research. http:\/\/www.npcnow.org\/system\/files\/research\/download\/experimental_nonexperimental_study_final.pdf"},{"key":"1487_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40259-013-0036-3","volume":"27","author":"Visser","year":"2013","unstructured":"Visser J, Feuerstein I, Stangler T et al (2013) Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 27:495\u2013507","journal-title":"BioDrugs"},{"key":"1487_CR27","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72:1613\u20131620","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1487-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-014-1487-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1487-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:37:27Z","timestamp":1559061447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-014-1487-8"}},"subtitle":["Entwicklung und Ergebnisse klinischer Studien"],"short-title":[],"issued":{"date-parts":[[2015,9,9]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["1487"],"URL":"https:\/\/doi.org\/10.1007\/s00393-014-1487-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,9]]}}}